INmune Bio, Inc. (INMB) Investor Relations Documents

INmune Bio, Inc. (INMB) investor relations documents from the company's IR site: 8 press releases. Read in-app with summaries. First-party data.

Investor relations documents — source: company IR site

Published	Type	Document
2026-08-06	Press release	Aug 06, 2026 INmune Bio Inc. Announces Second Quarter 2026 Results and Highlights Regulatory, Manufacturing and C...
2026-07-31	Press release	Jul 31, 2026 INmune Bio Inc. to Report Second Quarter 2026 Financial Results and Provide Corporate Update on Thur...
2026-07-20	Press release	20 Jul INmune Bio Completes Commercial Manufacturing Milestone Supporting Planned Global Registration Filin... Read More
2026-07-15	Press release	15 Jul INmune Bio’s XPro1595 Prevents Brain-Injury-Induced Alzheimer's Pathology, Memory Loss, and P... Read More
2026-07-09	Press release	INmune Bio to Present Positive Phase 2 Imaging Data for XPro
2026-06-25	Press release	25 Jun INmune Bio Inc. Achieves MHRA Approval of PIP for CORDStrom™... Read More
2026-06-23	Press release	23 Jun INmune Bio Receives MHRA Written Alignment Supporting Planned 2026 UK Conditional Marketing Authoriz... Read More
2026-06-02	Press release	02 Jun INmune Bio Reports Statistically Significant Treatment Effect on Advanced White Matter MRI Biomarker... Read More

INMB overview · INMB earnings · INMB financials · INMB KPIs · INMB ownership · INMB peers · INMB filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.